AI Verdict
GMED has stronger fundamentals based on our AI analysis.
GMED vs GLUE Fundamental Comparison
| Metric | GMED | GLUE |
|---|---|---|
| Revenue | $2.9B | $123.7M |
| Net Income | $537.9M | $-38.6M |
| Net Margin | 18.3% | -31.2% |
| ROE | 11.8% | -16.6% |
| ROA | 10.1% | -8.6% |
| Current Ratio | 4.26x | 6.12x |
| Debt/Equity | 0.00x | 0.00x |
| EPS | $3.92 | N/A |
Green = Better metric | Red = Weaker metric
You Might Also Compare
GMED vs GLUE: Frequently Asked Questions
Is GMED or GLUE a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), GMED has stronger fundamentals. GMED is rated BUY (78% confidence) while GLUE is rated HOLD (69% confidence). This is not investment advice.
How does GMED compare to GLUE fundamentally?
GLOBUS MEDICAL INC has ROE of 11.8% vs Monte Rosa Therapeutics, Inc.'s -16.6%. Net margins are 18.3% vs -31.2% respectively.
Which stock pays higher dividends, GMED or GLUE?
GMED has a dividend yield of N/A or no dividend while GLUE has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in GMED or GLUE for long term?
For long-term investing, consider that GMED has BUY rating with 78% confidence, while GLUE has HOLD rating with 69% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about GMED vs GLUE?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For GMED vs GLUE, the AI consensus favors GMED based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.